{
    "clinical_study": {
        "@rank": "60562", 
        "arm_group": [
            {
                "arm_group_label": "ASP2408 dose escalation cohort", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo dose escalation cohort", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to assess the safety, tolerability, and pharmacokinetics (PK)\n      of single ascending intravenous (IV) doses of ASP2408 in non-elderly, healthy male and\n      female subjects and to evaluate the pharmacodynamics of ASP2408."
        }, 
        "brief_title": "A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects", 
        "completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Subjects", 
            "Pharmacokinetics of ASP2408"
        ], 
        "detailed_description": {
            "textblock": "This is single-dose escalation study composed of 8 sequential cohorts of healthy subjects\n      receiving increasing doses of intravenously administered ASP2408 or matching placebo.\n      Subjects will be confined in the clinic for 8 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject weighs at least 50 kg, and has a body mass index (BMI) of 18.0 to 32.0 kg/m2,\n             inclusive.\n\n          -  Results of subject's 12-lead electrocardiogram (ECG) are normal or, if abnormal, the\n             abnormality is not clinically significant as determined by the investigator.\n\n          -  Female subject must be at least two years postmenopausal OR surgically sterile (with\n             documentation provided by a healthcare professional) and not pregnant or lactating.\n\n          -  Male subject agrees to the use of male condoms until the end of study or 60 days post\n             dose, whichever is longer.\n\n          -  Subject is highly likely to comply with the protocol and complete the study.\n\n        Exclusion Criteria:\n\n          -  Subject has a history of any clinically significant cardiac, endocrinologic,\n             hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic,\n             dermatologic, psychiatric, renal, and/or other major disease or malignancy excluding\n             adequately treated non-melanoma skin cancer.\n\n          -  Subject has a history of severe allergic or anaphylactic reactions.\n\n          -  Subject is a female of child-bearing potential.\n\n          -  Subject has a history of consuming more than 14 units of alcoholic beverages per week\n             or has a history of alcoholism or drug/chemical/ substance abuse within past 2 years\n             (Note: one unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits).\n\n          -  Subject has a positive test for alcohol or drugs of abuse.\n\n          -  Subject has/had a symptomatic, viral, bacterial (including upper respiratory\n             infection), or fungal (non-cutaneous) infection within 1 week prior to clinic\n             check-in.\n\n          -  Subject has a past history of opportunistic infection.\n\n          -  Subject has a supine mean systolic blood pressure < 90 or > 160 mmHg and a mean\n             diastolic blood pressure < 50 or > 90 mmHg, or mean pulse rate higher than 100 beats\n             per min (bpm).\n\n          -  Subject is known positive for human immunodeficiency virus (HIV) antibody.\n\n          -  Subject has a positive TB skin test or Quantiferon Gold test or T-SPOT\u00ae test at\n             Screening.\n\n          -  Subject has a positive test for hepatitis C antibody, or positive test for hepatitis\n             B surface antigen (HBsAg), or positive hepatitis B core antibody.\n\n          -  Subject's laboratory test results:\n\n               -  alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), are\n                  greater than 1.5 times the upper limit of normal\n\n               -  are outside the normal limits and considered by the investigator to be\n                  clinically significant with regard to the remaining per-protocol laboratory\n                  tests.\n\n          -  Subject received any vaccine within 60 days prior to study drug administration.\n\n          -  Subject received any systemic immunosuppressant agent within 2 months prior to study\n             drug administration.\n\n          -  Subject has previously received any antibody or therapeutic biologic product prior to\n             study drug administration.\n\n          -  Subject received any systemic steroid within 2 months or steroid inhaler within 1\n             month prior to study drug administration.\n\n          -  Subject has had treatment with prescription, non-prescription or complementary and\n             alternative medicines (CAM) within 14 days prior to study drug administration.\n\n          -  Subject has received an experimental agent within 30 days or five half-lives,\n             whichever is longer, prior to study drug administration.\n\n          -  Subject is participating in another clinical trial or has participated in another\n             dose group of the current trial.\n\n          -  Subject has had any significant blood loss, donated one unit (450 mL) of blood or\n             more, or received a transfusion of any blood or blood products within 60 days or\n             donated plasma within 7 days prior to clinic admission on Day -1.\n\n          -  Subject has a history of heavy smoking or has used tobacco-containing products and\n             nicotine or nicotine-containing products in the past six months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125435", 
            "org_study_id": "2408-CL-0101"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASP2408 dose escalation cohort", 
                "description": "intravenous", 
                "intervention_name": "ASP2408", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo dose escalation cohort", 
                "description": "intravenous", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Healthy subjects", 
            "ASP2408", 
            "pharmacokinetics"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21225"
                }, 
                "name": "PAREXEL International"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Global Development, Inc.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Area Under the Concentration - Time curve from time 0 up to the last quantifiable concentration (AUClast)", 
                "measure": "Pharmacokinetic parameter of ASP2408:AUClast", 
                "safety_issue": "No", 
                "time_frame": "Days 1-8, 15, 22, 29, 43, 60, 90"
            }, 
            {
                "description": "Area Under the Concentration - Time curve from time 0 extrapolated to infinity (AUCinf)", 
                "measure": "Pharmacokinetic parameter of ASP2408: AUCinf", 
                "safety_issue": "No", 
                "time_frame": "Days 1 -8, 15, 22, 29, 43, 60, 90"
            }, 
            {
                "description": "Maximum concentration (Cmax)", 
                "measure": "Pharmacokinetic parameter of ASP2408:Cmax", 
                "safety_issue": "No", 
                "time_frame": "Days 1-8, 15, 22, 29, 43, 60, 90"
            }, 
            {
                "measure": "Safety assessed by adverse events, laboratory tests, immunoglobulin, 12-lead electrocardiograms (ECGs), vital signs and anti-2408 antibody formulation", 
                "safety_issue": "No", 
                "time_frame": "up to 90 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125435"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time to attain Cmax (tmax), apparent terminal elimination half-life (t1/2), Terminal phase volume (Vz), Total Body Clearance (CLtot)", 
                "measure": "Composite of pharmacokinetics of ASP2408: tmax, t1/2, Vz, CLtot", 
                "safety_issue": "No", 
                "time_frame": "Days 1-8, 15, 22, 29, 43, 60, 90"
            }, 
            {
                "measure": "Pharmacodynamic parameters of ASP2408: CD80 and CD86 receptor occupancy", 
                "safety_issue": "No", 
                "time_frame": "Days 1-3, 5, 8, 15, 22, 29, 43, 60, 90"
            }, 
            {
                "measure": "Total lymphocyte count", 
                "safety_issue": "No", 
                "time_frame": "Days 1-3, 5, 8, 15, 22, 29, 43, 60, 90"
            }, 
            {
                "measure": "Peripheral lymphocyte subset quantification", 
                "safety_issue": "No", 
                "time_frame": "Days 1-3, 5, 8, 15, 22, 29, 43, 60, 90"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Global Development, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}